Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19975206 | 1.00 | P2RX7 (0.54) | P2RX7KMT2AALDH1A1GAAHCRTR1 | |
| SCHEMBL10408410 | 1.00 | P2RX7 (0.54) | P2RX7KMT2AALDH1A1GAAHCRTR1 | |
| SCHEMBL19975238 | 0.88 | ALDH1A1 (0.54) | P2RX7KMT2AALDH1A1GAAHCRTR1 | |
| SCHEMBL19974867 | 0.88 | ALDH1A1 (0.54) | P2RX7KMT2AALDH1A1GAAHCRTR1 | |
| SCHEMBL289574 | 0.88 | P2RX7 (0.56) | P2RX7KMT2AALDH1A1GAAHCRTR1 | |
| SCHEMBL288652 | 0.88 | P2RX7 (0.56) | P2RX7KMT2AALDH1A1GAAHCRTR1 | |
| SCHEMBL288651 | 0.88 | P2RX7 (0.56) | P2RX7KMT2AALDH1A1GAAHCRTR1 | |
| SCHEMBL289716 | 0.87 | GAA (0.58) | P2RX7KMT2AALDH1A1GAAHCRTR1 | |
| SCHEMBL1613647 | 0.87 | GAA (0.58) | P2RX7KMT2AALDH1A1GAAHCRTR1 | |
| SCHEMBL17940653 | 0.87 | KMT2A (0.52) | P2RX7KMT2AALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052498-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS | Council of Scientific & Industrial Research (IN) | 2016-08-10 | — | — | EP | disclosed |
| US-20160214983-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-07-28 | — | — | US | disclosed |
| WO-2015044951-A1 | 3,7-DIAZABICYCLO[3.3.1 ]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214983-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS | TBXA2R, PDGFRA, TBXAS1 | P2RX7 87/4885KMT2A 3077/4885ALDH1A1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.